

ABT® BioTechnological Water in Vitro and in Vivo Cosmetic Performance Data

Cosmetic Efficacy Data Set (in vitro & in vivo):

Developed using experimental protocols in collaboration with Etichub (Spin-off, University of Pavia) and INT.E.G.RA | Res Pharma.

Efficacy Profile: Evaluation based on instrumental measurements and consumer self-assessment.

This document provides scientific support data for cosmetic performance claims in accordance with Regulation (EU) No. 655/2013.

Patent No. 102015000038121

Anti-ageing cosmetic composition and method for its preparation.



A DIFFERENT SKINCARE PERFORMANCE TECHNOLOGY

Conventional Cosmetics

- Most cosmetic technologies work on the cell: adding, stimulating, repairing.

ABT® is a proprietary water-based cosmetic technology developed around a different formulation hypothesis.

- ABT® is Natì's proprietary biophysical approach, developed by its research laboratories. Its theoretical framework draws on research on water coherence domains (Del Giudice, Preparata).
- The model explains how ABT® was designed; it has not been independently established. What has been measured by external partners is cosmetic performance, in vitro and in a placebo-controlled in vivo study.
- The results concern cosmetic parameters only and do not imply pharmacological or medical activity.



External Testing Partners



Etichub Spin-off of the University of Pavia

Etichub is a **cosmetic laboratory** specialised in cosmetic consulting, testing, and the development of cosmetic products and ingredients.

In vivo studies on ABT® 9.0

Instrumental evaluations

Claim substantiation under EU Reg. 655/2013

Animal-free protocols



INT.E.G.RA | Res Pharma C.A.O. Laboratory

Scientific supervision: Dr Federica D'Abrosca, Biologist, Head of Cellular Biology Laboratory.

In vitro cell biology studies on ABT® 8.0

Human Fibroblast cell lines

OECD-adopted methods

Report: 18120_NT_EFF

Controlled in Vivo Study

40

Female Subjects

Aged 35-65

28

Days Duration

Placebo-controlled comparison
Placebo: bulk water

+65%

Hydration

Instrumentally measured in a placebo-controlled study

Product Tested

ABT® 9.0 BioTechnological Water (97.2% concentration) with Energy Filler.

Compliance & Institution

Testing Institution: Etichub · Spin-off
University of Pavia (2025)
Regulation (EU) No. 655/2013

The principal efficacy outcomes reported here are supported by instrumental measurements; consumer self-assessment is presented separately.
The study evaluated the finished ABT® 9.0 formulation with Energy Filler®. It did not isolate the individual contribution of each component.

The photo is for illustrative purposes only and does not represent the control group.



Measured Cosmetic Outcomes After 28 Days

Average Roughness

-28%

Reduction in instrumentally measured average roughness

Surface Micro-Roughness

-26%

Reduction in instrumentally measured surface micro-roughness

Skin Radiance

+25%

Increase in instrumentally measured skin radiance

Hydration

+65%

Instrumentally measured vs. placebo over 28 days

Self-Assessment: 80% of participants reported visible improvement in brightness, smoothness and skin comfort

No Adverse Changes Observed in Assessed Skin Microbiota Parameters

16S Metagenomic Analysis Etichub
Skin Microbiota Assessment

According to the 16S metagenomic analysis conducted by Etichub, no adverse changes were observed in the assessed skin microbiota parameters during the evaluation period.

In Vitro Observations on Human Fibroblasts

Human fibroblast cell lines · ABT® 8.0 versus bulk-water control · INT.E.G.RA | Res Pharma · C.A.O. Laboratory · Report 18120_NT_EFF

- +21.5% Cellular ATP
- +38.5% Elastin production
- 97% IL-6 and IL-8 interleukins
- 15% Free radicals
- 25% Photo-ageing markers

In the reported in vitro study, ABT® 8.0 was associated with increased fibroblast viability and elastin production.

Tests were performed in two parallel setups:

- (1) direct contact condition: ABT 8.0 applied directly into the cell culture medium;
- (2) physical separation condition: ABT 8.0 applied exclusively to the exterior surface of sealed polypropylene cell culture containers, with no direct molecular contact between ABT 8.0 and the cell culture medium or cells.

In vitro findings describe cellular responses under laboratory conditions. They do not establish clinical efficacy or therapeutic activity.

Cosmetic Scope and Claim Boundaries

This Document Does Not Refer To:

- Medical or therapeutic effects
- Systemic or internal biological activity
- Prevention, treatment or diagnosis of diseases

ABT® Mode of Cosmetic Action:

- The product is positioned and evaluated exclusively as a cosmetic and is not intended to produce pharmacological or medical effects.

Nati's biophysical approach is a proprietary formulation developed by its research laboratories. Its theoretical model is a working framework and has not been independently established. Cosmetic performance has been measured by external partners through a placebo-controlled in vivo study with instrumental measurements, and through in vitro tests on human fibroblasts.





Cosmetic Efficacy Data Set (in vitro & in vivo) developed using experimental protocols in collaboration with Etichub (Spin-off, University of Pavia) and INT.E.G.RA | Res Pharma.

Patent No. 102015000038121 · Commission Regulation (EU) No. 655/2013 on common criteria for cosmetic claims

For further information on our methodology, in vitro protocols or how these results translate into professional treatment performance, please contact:

Alberto Galli

Business Development

export@nati.it

nati.it